Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the gastrointestinal tract. Current therapeutic options include surgery and targeted molecular approaches such as imatinib and sunitinib. Our aim was to establish patient-derived GIST xenografts for the use of screening new drugs and improving current treatment regimens used in GIST. In this present study, we investig...

photodetectors Ayman Karar, Narottam Das, Chee Leong Tan, Kamal Alameh, Yong Tak Lee, and Fouad Karouta Electron Science Research Institute, Edith Cowan University, Joondalup, WA, Australia School of Photonics Science, Gwangju Institute of Science and Technology (GIST), Gwangju, South Korea Department of Information and Communications, GIST, Gwangju, South Korea Department of Nanobio Materials ...

Gastrointestinal stromal tumors (GIST) are rare neoplasms that mostly affect patients over the age of 50, with no gender predilection1,2. The diagnosis of GIST is made by means of immunohistochemistry testing for CD117 (c-kit), and combination treatment with surgical intervention and adjuvant chemotherapy has produced good outcomes3. We report a case of gastric GIST diagnosed after an episode o...

simultaneous a collision tumor of stomach consisting of adenocarcinoma and gastrointestinal stromal tumor (gist) is very rare based on our knowledge. this coexistence has rarely been reported in literatures. we report a case of 64-year-old woman who has diagnosed with prepyloric poorly-differentiated diffuse signet-ring cell type adenocarcinoma and has undergone an elective d2 total gastrectomy...

Gastrointestinal stromal tumors (GISTs) are the most common among gastrointestinal mesenchymal tumors, but its prognosis has not been accurately predicted by the current risk stratification guidelines, National Institutes of Health classification. In this study, we evaluated the predictive factors for GIST prognosis in a retrospective analysis of 332 patients. The data collected included tumor ...

Imatinib is the first-line drug for gastrointestinal stromal tumors (GISTs), as mutated KIT is closely associated with the occurrence of GIST. However, Imatinib resistance (IMA-resistance) occurs inevitably in most GIST patients. Although the over-expression of KIT in GIST is one of the major factors contributing to IMA-resistance, the underlying mechanism is still unclear. In this study, we de...

The IETF’s Next Steps in Signaling (NSIS) framework provides an up-to-date signaling protocol suite that can be used to dynamically install, maintain, and manipulate state in network nodes. In its two-layered architecture, the General Internet Signaling Transport (GIST) protocol is responsible for the transport and routing of signaling messages. The strong presence of Network Address Translatio...

BACKGROUND Although the clinical benefit of imatinib adjuvant therapy for high-risk patients with gastrointestinal stromal tumor (GIST) has been proven, the recurrence rate still remains high. This study aimed to sub-divide high-risk GIST patients with some "very high-risk" factors for more precise prognostic indicator, and possible association with efficiency of imatinib adjuvant therapy. ME...